The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Liver resectability following mFOLFOX6 with bevacizumab as the first-line treatment of unresectable liver limited metastases from colorectal cancer in Japanese patients (KSCC 0802).
Hironori Samura
No relevant relationships to disclose
Toru Beppu
No relevant relationships to disclose
Yasunori Emi
No relevant relationships to disclose
Yoshihiro Kakeji
Honoraria - Chugai Pharma
Hiroshi Saeki
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Fumihiko Fujita
No relevant relationships to disclose
Masahumi Inomata
No relevant relationships to disclose
Terumitsu Sawai
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Shoji Natsugoe
No relevant relationships to disclose
Yutaka Ogata
No relevant relationships to disclose
Shoji Tokunaga
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Chugai Pharma; Yakult